Q-omics provides the consensus-scored CHCHD4P5 profile across patient tissues and cancer cell-line models. CHCHD4P5 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CHCHD4P5 is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, CHCHD4P5 RNA expression shows 14,244 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, BRCA, and LSCC as cancer lineages where CHCHD4P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHCHD4P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHCHD4P5 survival associations across molecular data types. CHCHD4P5 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHCHD4P5 RNA expression–survival associations across cancer types. High CHCHD4P5 expression shows unfavorable associations in KIRC, MESO, OV, COAD, CHOL and DLBC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CHCHD4P5 RNA expression.
This table summarizes CHCHD4P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for CHCHD4P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHCHD4P5 shows higher tumor expression in BRCA and STAD. The BRCA box plot shows higher CHCHD4P5 RNA expression in tumor versus normal tissue (log2 FC = +0.233, t-test p = .013).
This table shows molecular features associated with CHCHD4P5 in patient tissues and cancer cell lines. In patient samples, CHCHD4P5 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
